Seminars in Arthroplasty
Volume 18, Issue 3 , Pages 184-191 , September 2007

Detecting Thrombophilia, Hypofibrinolysis and Reduced Nitric Oxide Production in Osteonecrosis

  • Charles J. Glueck, MD

      Affiliations

    • Cholesterol Center, Jewish Hospital, Cincinnati, OH.
    • Corresponding Author InformationAddress reprint requests to Charles J. Glueck, MD, Cholesterol Center, ABC Building, 3200 Burnet Avenue, Cincinnati, OH.
    • ,
  • Richard A. Freiberg, MD

      Affiliations

    • Cincinnati Veterans Administration Hospital, Cincinnati, OH.
    • ,
  • Ping Wang, PhD

      Affiliations

    • Cholesterol Center, Jewish Hospital, Cincinnati, OH.

References 

  1. Bjorkman A, Burtscher IM, Svensson PJ, et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg. 2005;125:51–55
  2. Jones JP. Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis. In:  Urbaniak JR,  Jones JP editor. Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1997;p. 89–97
  3. Jones LC, Mont MA, Le TB, et al. Procoagulants and osteonecrosis. J Rheumatol. 2003;30:783–791
  4. Jones LC, Hungerford DS. Osteonecrosis: Etiology, diagnosis, and treatment. Curr Opin Rheumatol. 2004;16:443–449
  5. Glueck CJ, Glueck HI, Mieczkowski L, et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?. Thromb Haemost. 1993;69:460–465
  6. Glueck CJ, Freiberg R, Glueck HI, et al. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol. 1995;48:213–220
  7. Glueck CJ, Freiberg R, Tracy T, et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop. 1997;43–56
  8. Glueck CJ, Fontaine RN, Gruppo R, et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop. 1999;133–146
  9. Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop. 2001;19–33
  10. Glueck CJ, Freiberg RA, Sieve L, et al. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005;164–170
  11. Glueck CJFR, Oghene J, Fontaine RN, et al. Association Between the T-786C eNOS polymorphism and idiopathic osteonecrosis of the head of the femur. J Bone Joint Surg Am. 2007;(in press)
  12. Glueck CJFR, Oghene J, Fontaine RN, et al. Association between the T-786C eNOS polymorphism and idiopathic osteonecrosis of the hip. J Invest Med Abstr. 2007;(in press)
  13. Koo KH, Lee JS, Lee YJ, et al. Endothelial nitric oxide synthase gene polymorphisms in patients with nontraumatic femoral head osteonecrosis. J Orthop Res. 2006;24:1722–1728
  14. Arlet J, Ficat P. Diagnosis of primary femur head osteonecrosis at stage 1 (preradiologic stage). Rev Chir Orthop Reparatrice Appar Motil. 1968;54:637–648
  15. Glueck CJ, Glueck HI, Tracy T, et al. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia. Metabolism. 1993;42:1410–1419
  16. Wahlander K, Larson G, Lindahl TL, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost. 2002;87:580–585
  17. Westrich GH, Weksler BB, Glueck CJ, et al. Correlation of thrombophilia and hypofibrinolysis with pulmonary embolism following total hip arthroplasty: An analysis of genetic factors. J Bone Joint Surg Am. 2002;84A:2161–2167
  18. Salvati EA, Della Valle AG, Westrich GH, et al. The John Charnley Award: Heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 2005;441:40–55
  19. Mont MA, Jones LC, Rajadhyaksha AD, et al. Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop Relat Res. 2004;422:154–163
  20. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94–124
  21. Ficat P. Cortisone associated necrosis of bone. In:  Hungerford D editors. Ischemia and Necrosis of Bone. Baltimore, MD: Williams and Wilkins; 1980;p. 171–176
  22. McKee MD, Waddell JP, Kudo PA, et al. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: A report of 15 cases. Can Med Assoc J. 2001;164:205–206
  23. Van Veldhuizen PJ, Neff J, Murphey MD, et al. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol. 1993;44:243–248
  24. Glueck CJ, Glueck HI, Greenfield D, et al. Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg–Perthes disease. Pediatr Res. 1994;35:383–388
  25. Glueck CJ, McMahon RE, Bouquot J, et al. Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:557–566
  26. Glueck CJ, Crawford A, Roy D, et al. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg–Perthes disease. J Bone Joint Surg Am. 1996;78:3–13
  27. Glueck CJ, McMahon RE, Bouquot JE, et al. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med. 1997;130:540–543
  28. Glueck CJ, Brandt G, Gruppo R, et al. Resistance to activated protein C and Legg–Perthes disease. Clin Orthop. 1997;139–152
  29. Glueck CJ, Freiberg RA, Crawford A, et al. Secondhand smoke, hypofibrinolysis, and Legg–Perthes disease. Clin Orthop. 1998;159–167
  30. Glueck CJ, McMahon RE, Bouquot JE, et al. Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain. Cranio. 1998;16:143–153
  31. Glueck CJ, Phillips HG, Cameron D, et al. Estrogen replacement in a protein S deficient patient leads to diarrhea, hyperglucagonemia, and osteonecrosis. Journal of the Pancreas. 2001;2:323–329
  32. Glueck CJ, Freiberg RA, Fontaine RN, et al. Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. Expert Opin Invest Drugs. 2001;10:1309–1316
  33. Glueck CJ, Freiberg RA, Wang P. Role of thrombosis in osteonecrosis. Curr Hematol Rep. 2003;2:417–422
  34. Gruppo R, Glueck CJ, Wall E, et al. Legg–Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J Pediatr. 1998;132:885–888
  35. Balasa VV, Gruppo RA, Glueck CJ, et al. Legg–Calve–Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004;86A:2642–2647
  36. Jones LC, Mont MA, Le TB, et al. Procoagulants and osteonecrosis. J Rheumatol. 2003;30:783
  37. Koo KH, Kim R, Cho SH, et al. Angiography, scintigraphy, intraosseous pressure, and histologic findings in high-risk osteonecrotic femoral heads with negative magnetic resonance images. Clin Orthop. 1994;127–138
  38. Korompilias AV, Gilkeson GS, Ortel TL, et al. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop. 1997;174–180
  39. Korompilias AV, Ortel TL, Urbaniak JR. Coagulation bnormalities in patients with hip osteonecrosis. Orthop Clin North Am. 2004;35:265–271
  40. Kubo T, Tsuji H, Yamamoto T, et al. Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop. 2000;306–311
  41. Kutlar A, Kutlar F, Turker I, et al. The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin. 2001;25:213–217
  42. Bjorkman A, Svensson PJ, Hillarp A, et al. Factor V leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop. 2004;168–172
  43. Boss JH, Misselevich I. Osteonecrosis of the femoral head of laboratory animals: The lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol. 2003;40:345–354
  44. Liu SL, Ho TC. The role of venous hypertension in the pathogenesis of Legg–Perthes disease: A clinical and experimental study. J Bone Joint Surg Am. 1991;73:194–200
  45. Norman D, Reis D, Zinman C, et al. Vascular deprivation-induced necrosis of the femoral head of the rat: An experimental model of avascular osteonecrosis in the skeletally immature individual or Legg–Perthes disease. Int J Exp Pathol. 1998;79:173–181
  46. Zalavras C, Dailiana Z, Elisaf M, et al. Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Invest. 2000;30:215–221
  47. Zalavras CG, Vartholomatos G, Dokou E, et al. Genetic background of osteonecrosis: Associated with thrombophilic mutations?. Clin Orthop. 2004;251–255
  48. Jones JJ. Activating intravascular coagulation and causing nontraumatic osteonecrosis. In:  Urbaniak JR,  Jones JP editor. Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1997;p. 89–97
  49. Mont MA, Glueck CJ, Pacheco IH, et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24:654–662
  50. Nilsson IM, Krook H, Sternby NH, et al. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand. 1961;169:323–337
  51. Pierre-Jacques H, Glueck CJ, Mont MA, et al. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis: A case report. J Bone Joint Surg Am. 1997;79:1079–1084
  52. Eldridge J, Dilley A, Austin H, et al. The role of protein C, protein S, and resistance to activated protein C in Legg–Perthes disease. Pediatrics. 2001;107:1329–1334
  53. Szepesi K, Posan E, Harsfalvi J, et al. The most severe forms of Perthes’ disease associated with the homozygous Factor V Leiden mutation. J Bone Joint Surg Br. 2004;86:426–429
  54. Bouquot JE, LaMarche MG. Ischemic osteonecrosis under fixed partial denture pontics: Radiographicand microscopic features in 38 patients with chronic pain. J Prosthet Dent. 1999;81:148–158
  55. Lieberman JR. Core decompression for osteonecrosis of the hip. Clin Orthop. 2004;29–33
  56. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–907
  57. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163–170
  58. Research CotBTS. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism (Research Committee of the British Thoracic Society). Lancet. 1992;340:873–876
  59. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661–1665
  60. Schulman S. Oral anticoagulation in venous thromboembolism: Decisions based on more than mere feelings. J Intern Med. 1999;245:399–403
  61. Thaler HW, Roller RE, Greiner N, et al. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma. 2001;51:518–521
  62. Tan X, Cai D, Wu Y, et al. Comparative analysis of serum proteomes: Discovery of proteins associated with osteonecrosis of the femoral head. Transl Res. 2006;148:114–119
  63. Glueck CJ, Glueck HI, Welch M, et al. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost. 1994;71:195–198
  64. Sun W, Li ZR, Shi ZC, et al. Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. Int Orthop. 2006;30:143–146
  65. Ferrari P, Schroeder V, Anderson S, et al. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation. 2002;74:1147–1152
  66. Miyanishi K, Kamo Y, Ihara H, et al. Risk factors for dysbaric osteonecrosis. Rheumatology (Oxf). 2006;45:855–858
  67. Bjorkman A, Svensson PJ, Hillarp A, et al. Factor V leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004;425:168–172
  68. Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001;386:19–33
  69. Blanche P, Si-Larbi AG, Jouve P. Femoral head necrosis and hyperhomocysteinemia. J Rheumatol. 2001;28:1469
  70. Glueck CJ, Shaw P, Lang JE, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995;75:132–136
  71. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3:79–84
  72. Lavigne G, Mercier E, Quere I, et al. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost. 2003;1:2134–2139
  73. Legnani C, Cini M, Cosmi B, et al. Risk of deep vein thrombosis: Interaction between oral contraceptives and high factor VIII levels. Haematologica. 2004;89:1347–1351
  74. Schambeck CM, Hinney K, Haubitz I, et al. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2001;21:289–292
  75. Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680–683
  76. Berger CE, Kroner A, Stiegler H, et al. Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor. Clin Orthop Relat Res. 2002;397:342–349
  77. Posan E, Szepesi K, Gaspar L, et al. Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral head. Blood Coagul Fibrinolysis. 2003;14:243–248
  78. Berger CE, Kluger R, Urban M, et al. Elevated levels of lipoprotein(a) in familial bone marrow edema syndrome of the hip. Clin Orthop Relat Res. 2000;377:126–131
  79. Campos LM, Kiss MH, D’Amico EA, et al. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus. 2003;12:820–826
  80. Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus. 2006;15:354–357
  81. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: A clinical review. Arch Intern Med. 2004;164:1965–1976
  82. Glueck CJ, Haque M, Winarska M, et al. Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: A pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger’s disease. Clin Appl Thromb Hemost. 2006;12:427–439
  83. Yoon S, Shin C, Park HY, et al. Endothelial nitric oxide synthase gene is associated with vessel stenosis in Korean population. Clin Chim Acta. 2005;353:177–185
  84. Nakayama M, Yasue H, Yoshimura M, et al. T(-786)–> C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000;86:628–634
  85. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001;88:756–762
  86. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9:1370–1376
  87. Namba T, Koike H, Murakami K, et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation. 2003;108:2250–2257
  88. Samuels A, Perry MJ, Gibson RL, et al. Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. Bone. 2001;29:24–29
  89. Hofmann S, Mazieres B. [Osteonecrosis: Natural course and conservative therapy]. Orthopade. 2000;29:403–410
  90. Koo KH, Kim R, Ko GH, et al. Preventing collapse in early osteonecrosis of the femoral head: A randomised clinical trial of core decompression. J Bone Joint Surg Br. 1995;77:870–874
  91. Stulberg BN, Davis AW, Bauer TW, et al. Osteonecrosis of the femoral head: A prospective randomized treatment protocol. Clin Orthop. 1991;140–151
  92. Hresko MT, McDougall PA, Gorlin JB, et al. Prospective reevaluation of the association between thrombotic diathesis and Legg–Perthes disease. J Bone Joint Surg Am. 2002;84A:1613–1618
  93. Boss JH, Misselevich I, Bejar J, et al. Experimentally gained insight-based proposal apropos the treatment of osteonecrosis of the femoral head. Med Hypotheses. 2004;62:958–965
  94. Brenig B, Leeb T, Jansen S, et al. Analysis of blood clotting factor activities in canine Legg–Calve–Perthes’ disease. J Vet Intern Med. 1999;13:570–573
  95. Laroche M. Intraosseous circulation from physiology to disease. Joint Bone Spine. 2002;69:262–269
  96. Norman D, Miller Y, Sabo E, et al. The effects of enoxaparin on the reparative processes in experimental osteonecrosis of the femoral head of the rat. Apmis. 2002;110:221–228

 One or more of the authors (CJG) has received funding from the Jewish Hospital Medical Research Council. None of the authors has any conflicts of interest.The Jewish Hospital Institutional Review Board approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research, and that informed consent was obtained.

PII: S1045-4527(07)00039-9

doi: 10.1053/j.sart.2007.06.005

Seminars in Arthroplasty
Volume 18, Issue 3 , Pages 184-191 , September 2007

Article Tools

* Image Usage & Resolution